Revive Therapeutics Ltd RVVTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVVTF is a good fit for your portfolio.
News
-
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
-
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
-
Revive Therapeutics Provides Corporate Update
-
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.02–0.02
- 52-Week Range
- $0.02–0.07
- Bid/Ask
- $0.02 / $0.02
- Market Cap
- $7.20 Mil
- Volume/Avg
- 84,552 / 309,664
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.revivethera.com
Valuation
|
Metric
|
RVVTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVVTF
|
|---|---|
Quick Ratio | 0.26 |
Current Ratio | 0.31 |
Interest Coverage | −133.90 |
Quick Ratio
RVVTF
Profitability
|
Metric
|
RVVTF
|
|---|---|
Return on Assets (Normalized) | −25.73% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −35.33% |
Return on Assets
RVVTF
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Yvmplsrdn | Zslj | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Wqtyzqwdw | Fpqdshl | $68.4 Bil | |
HLN
| Haleon PLC ADR | Jntkhdhcq | Jsvf | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lcychdq | Lbmp | $14.5 Bil | |
VTRS
| Viatris Inc | Phdthcqn | Nxlfk | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Yvkkvznl | Krk | $12.0 Bil | |
CTLT
| Catalent Inc | Jqptyhlhp | Mpjbwgj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Sgfzjhck | Pdszx | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Mnldsbrs | Mznrb | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cyzpqrp | Qltvx | $3.5 Bil |